Moteur de recherche d’entreprises européennes
Financement de l’UE (4 999 023 €) : Consolider les capacités d’EATRIS-ERIC pour la Médecine Personnalisée Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Consolider les capacités d’EATRIS-ERIC pour la Médecine Personnalisée
In the first five years of operations, EATRIS has shown strong proof of concept of the value of the services portfolio, with users ranging from academia, SMEs, large pharma, to biotech and research funding organisations. The overarching aim of EATRIS-Plus is to support the long-term sustainability (LTS) of EATRIS by delivering innovative scientific tools to the research community, strengthening the infrastructure’s financial model and reinforcing EATRIS leadership in the European Research Area (ERA), particularly in the field of Personalised Medicine (PM) research and development. Specific objectives are: (i) To consolidate EATRIS capacities in the field of PM to better serve academia and industry and augment the number of EATRIS Innovation Hubs with large pharma; (ii) To further strengthen the LTS of EATRIS financial model; (iii) To drive patient empowerment through active involvement in the infrastructure’s operations; (iv) To expand strategic partnerships with Research Infrastructures and other relevant stakeholders. The proposal relies on a scientific and technological programme combined with capacity-building activities across 16 EU countries, with the support of two umbrella organisations representing patient organisations and SMEs. EATRIS-Plus will help pooling and exploiting the translational academic capacities of the infrastructure in omic technologies to enable researchers to better address the scientific and societal challenge of PM. Additionally, the coordination office and 13 existing national nodes of the infrastructure will participate in implementing joint outreach, training, industry engagement and international collaboration activities to further build national capacity, increase users’ trust and strengthen EATRIS and the ERA global scientific leadership.
| 144 720 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 143 413 € |
| EUROPEAN AIDS TREATMENT GROUP e. V. | 0,00 € |
| 972 508 € | |
| Forum des Patients Europeens | 195 134 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 43 055 € |
| HELSINGIN YLIOPISTO | 368 761 € |
| 149 375 € | |
| ITA-SUOMEN YLIOPISTO | 40 024 € |
| Istituto Superiore DI Sanita | 133 344 € |
| 101 250 € | |
| Luxembourg Institute OF Health | 313 292 € |
| MMI CLINICAL RESEARCH DEVELOPMENT IRELAND | 0,00 € |
| Masarykova Univerzita | 0,00 € |
| Ospedale SAN Raffaele Srl | 0,00 € |
| Rigas Stradina Universitate | 93 438 € |
| 276 120 € | |
| 65 625 € | |
| Stichting Radboud Universitair Medisch Centrum | 432 260 € |
| 113 615 € | |
| 45 394 € | |
| THE PROVOST, FELLOWS Foundation SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN | 106 210 € |
| Universitetet I Oslo | 160 375 € |
| Univerza V Ljubljani | 137 750 € |
| Univerzita Palackeho V Olomouci | 571 000 € |
| Uppsala Universitet | 392 363 € |
https://cordis.europa.eu/project/id/871096
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Biocat La Fundacio Bioregio de Catalunya - Financement de l’UE (4 999 023 €) : Consolider les capacités d’EATRIS-ERIC pour la Médecine Personnalisée"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
